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Patient perceived ICS side effects 1319Results: Focus groups and interviews revealed 57 side effects that were associated
with ICS use. Cross-sectional survey results showed significant differences in side
effect perception between the four dosage groups for 31 items (all Pp0:01) and a
rising intensity with increasing ICS dose for total side effect score (Po0:001). For ICS
users reporting the most bothersome side effects (scoring X3 on 0–6 scale) there
was a rising prevalence as ICS dose increased for 34 items. A multivariate model
confirmed that mid and high ICS dosages were statistically significantly associated
with side effect perception after controlling for the other factors and covariates.
Conclusions: Higher daily ICS doses were associated with a higher intensity and a
higher prevalence of many patient perceived side effects, lending support to the call
for dose titration in clinical practice. Results indicate the usefulness of patient self-
report scales for understanding the burden of side effects of ICS in the community.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Inhaled corticosteroids (ICS) are currently the most
important medications for control of the underlying
airway inflammation of asthma,1 although earlier
prescribing of ICS, for longer periods and at higher
doses than in the past, have raised concerns about
potential side effects.2–4 Indeed, studies have
identified local and systemic side effects of ICS.
Some reported local ICS side effects include oral
thrush, cough and thirst,5,6 as well as hoarseness
and dysphonia for which the risk increases with
higher doses.4,5 Systemic side effects include dose
dependent bruising and thinning of the skin7,8 a
higher risk of posterior subcapsular cataract,9,10 a
higher risk of open-angle glaucoma11 and cases of
behavioural changes such as insomnia and listless-
ness.12
It is likely that our current knowledge of the
range and extent of ICS side effects as experienced
by patients in the community is underestimated.
The quality of side effect data is often limited by
the relatively short duration and selection criteria
for patients in clinical trials13 and, once a drug has
been licensed, by the low reporting rates by
physicians to pharmacovigilance organisations.14
Further, side effects associated with ICS by patients
may not be detected during routine clinical
practice15 and patients are unlikely to discuss their
concerns about ICS medication with their physi-
cian.16This is important since side effects may
influence treatment adherence,17,18 asthma
control and morbidity.19,20
Patient self-report questionnaires may provide
an important new method for understanding the
burden of drug side effects,21 such as those
associated with ICS use.
In this study, we aimed to elicit side effects
perceived by patients using qualitative methodol-ogy. We then investigated the existence of a dose
response and measured the prevalence and inten-
sity of these perceived side effects in groups of
patients stratified by ICS dose, in a cross-sectional
questionnaire survey.Methods
Qualitative item generation
Participants were inhaler users with asthma or
COPD aged X16 years who were recruited, either
via their General Practitioner or through media
advertisements in both Groningen (The Nether-
lands) and Aberdeen (Scotland). Participants were
recruited in two countries in order to optimise the
representativeness of participant experiences of
inhaled steroid side effect. Two methods of data
collection were employed: interview data supple-
mented initial focus group data to provide some
methodological triangulation. In-depth interviews
and focus groups were conducted by a qualitative
researcher who asked patients to talk about their
own experience of side effects that they associated
with their ICS use. Questions asked during qualita-
tive work were semi-structured. The facilitator
began by asking participants a broad general
question about experience of inhaler side effects,
and followed up initial responses with other
members of the group (during focus groups). The
facilitator was asked to focus participants as much
as possible on any side effect they had experi-
enced, that they believed was caused by their
steroid inhaler.
Participants gave their consent for the qualita-
tive work to be taped and later transcribed. The
qualitative research facilitator compiled a list of
side effects which emerged from the transcripts.
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J.M. Foster et al.1320One additional author and an independent
researcher also reviewed the transcripts, and a
consensus regarding the final side effect list was
reached by discussion. Side effect items that
emerged from the transcripts were subsequently
reviewed by an independent expert panel of
experienced respiratory researchers (see Acknowl-
edgements). The expert panel reached a consensus
regarding perceived side effects considered poten-
tially related to ICS use, based on their own clinical
and research experience. Items were discarded to
optimise the specificity of the scale for ICS side
effects. Only those items clearly unrelated to ICS
medication or items known to be side effects of
b2-agonist inhalers were removed by the panel, so
that as many reported side effects as possible could
be explored in this analysis. Items considered
related to ICS use were put onto the 7-point Likert
scale Inhaled Corticosteroid Questionnaire (ICQ) for
the cross-sectional survey (see Questionnaire in
Appendix A).Cross-sectional survey
In response to a postal invitation, participating
pharmacies volunteered to identify and recruit
eligible patients. Participating patients were
b2-agonist and corticosteroid inhaler users with
asthma or COPD, aged X16 years, who visited
community pharmacy and were recruited by con-
secutive invitation, in Groningen (The Netherlands)
and Grampian (Scotland). We recruited participants
in two countries in order to optimise the repre-
sentativeness of inhaler use, and of participant
experiences of inhaled steroid side effect. Eligible
patients had possessed a b2-agonist inhaler or taken
daily ICS medication for X3 months. Patients who
had taken oral corticosteroids within the last 3
months, or were currently taking nasal, topical or
ocular corticosteroids were excluded. We collected
patients’ inhaler name and type, number of puffs
per day normally taken, microgram dosage per
puff, age, gender, smoking status, post inhalation
rinsing behaviour, and other current medication.
Using a 7-point Likert scale questionnaire, consent-
ing participants self-reported how much they had
been affected by each listed side effect since they
had started using their inhalers (0 ¼ not at all;
1 ¼ a very little; 2 ¼ a little; 3 ¼ a moderate
amount; 4 ¼ quite a lot; 5 ¼ a great deal; 6 ¼ a
very great deal). Participants were reassured that
they may not have experienced any listed side
effect. Participants were divided into four medica-
tion groups based on their daily ICS dosage: group
1 ¼ b2-agonist without ICS, group 2p400 mg ICS,group 3 ¼ 401–800 mg ICS, group 44800 mg ICS. All
stated doses are BDP equivalent (BDP ¼ 800 mg,
BUD ¼ 800 mg, FP ¼ 500 mg).22,23 Approval for this
study was obtained from Grampian Research Ethics
Committee. Dutch ethical approval is not required
for the completion of a questionnaire.Analysis
Difference in intensity of side effect perception
between the four dosage groups, for each side
effect (score 0–6) and for total (cumulative) ICQ
score (score 0–100) was analysed using the Jonc-
kheere–Terpstra Test (SPSS v.11). For ease of
interpretation the total ICQ score (0–342) was
transformed to a cumulative total score out of
100 using the following formula: (Total participant
score/(6 57)100). Due to the number of statistical
tests performed a more stringent P-value of p0.01
was used to denote statistical significance. For side
effect items scored significantly differently in
intensity, we plotted the relative prevalence
(% patients scoring 40) by dosage group on a bar
chart. To illustrate patients’ experience of the
most potentially bothersome side effects, we also
calculated the relative prevalence of items affect-
ing patients a moderate amount or greater on the
ICQ scale (% patients scoring 3 or more on the scale)
by dosage group. Finally, we used a generalized
linear model (GLM) analysis (STATA) to establish the
relationship between ICS dosage group and ICQ
scoring. We calculated an average ICQ score which
took into account the 8 categories of the ICQ
(Table 3) to ensure equal category weighting. Given
that the ICQ scores were skewed towards zero we
took natural logs of the averaged total score having
initially added 1. This then served as the dependent
variable in a multivariate model. The GLM was an
appropriate process since we wished to assess if the
level of side effects were influenced not only by
daily dosage but to also adjust for several other
independent variables which were a mixture of
fixed factors and continuous variables. Hence, the
GLM process compared dosage while controlling for
fixed factors (gender, post-inhalation mouth rin-
sing, smoking) and covariates (age, daily puffs of
short acting b2-agonist and number of other current
medications used). For any one categorical inde-
pendent variable the analysis computed the coeffi-
cient for each level relative to one specific level in
this case always the base state (e.g. for dose: high,
mid and low dose ICS groups are all related back to
the non-ICS group). Similarly the significance was
relative to the base level.
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Qualitative item generation
Twenty-two current ICS users (15 male) partici-
pated. Their median age was 55 years and their
median daily (BDP equivalent) dosage of ICS was
800 mg (Table 1). Sixty-eight potential side effect
items were extracted from transcripts of 12 inter-
views and two focus groups. Eleven items wereTable 1 Patient characteristics for qualitative item gen
Age % Male Current daily
ICS dose
Total sample 55 (40–66) 68 800 (575–1000
(n ¼ 22)
Aberdeen 62 (54–67) 73 800 (400–1000
(n ¼ 11)
Groningen 42 (32–64) 64 800 (800–800)
(n ¼ 11)
All data medians and interquartile ranges unless otherwise specifi
Data missing for 8 patients.
Table 2 Patient characteristics for cross-sectional surve
Characteristics Total
sample
(n ¼ 395)
b2-agonist
without ICS
(n ¼ 66)
p
I
(
Mean age in years (range) 50.1 43.3 4
(16–85) (16–79) (
% Females 53.1 42.4 6
% Current smokers 28.5 31.8 2
% Rinsed mouth after ICS
inhalation
5
% Using number of puffs of SABA
None 56.2 15.4 5
1–2 15.9 35.4 1
3–4 19.4 33.8 1
More than 5 8.6 15.4 1
% Using number of other current medications
0 medications 35.2 50 4
1–2 medications 37.7 39.4 3
More than 3
medications
27.1 10.6 2
Analyses w2 unless otherwise specified.
yOne-way Anova.considered unrelated to ICS (see Table A1 in
Appendix A), leaving 57 agreed potential side
effect items.
Cross-sectional survey
Fifty-six per cent of invited patients returned their
questionnaires, enabling us to study 395 current
inhaler users (53% women, 29% current smokers)
with a mean age of 50 years (Table 2). There waseration.
Duration of Use
of current ICS in
months
% Diagnosed
with asthma
or COPD
% Using b2-
agonist
) 42 (11–87) 82 asthma 91
18 COPD
) 30 (10–81) 91 asthma 82
9 COPD
60 (28.5–102) 73 asthma 100
27 COPD
ed.
y.
400 mg
CS
n ¼ 109)
401–800 mg
ICS
(n ¼ 151)
4800 mg
ICS
(n ¼ 69)
P-value
8.1 52.1 55.7 o0.001y
16–84) (16–85) (19–77)
4.8 54.1 42.6 o0.01
1.5 31.1 30.9 NS
4.4 74.7 71.9 o0.01
4.1 71 67.2
6.3 11.7 4.7
8.4 13.8 18.8
1.2 3.4 9.4 o0.001
5 29.8 17.4
3.9 39.7 37.7
1.1 30.5 44.9 o0.001
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Figure 1 Prevalence of side effect perception by daily dosage group for the 31 items significantly different in Table 3.
Patient perceived ICS side effects 1323significant variability between the four dosage
groups for both age (Po0:001) and gender
(Po0:01). Individuals who used higher doses tended
to be older and females used lower mean doses
(639 mg) than males (710 mg). Smoking status did not
differ between groups. Sixty-seven per cent of ICS
patients rinsed their mouth after inhaling their
medication. Non-ICS users tended to use more
short-acting b2-agonist than ICS users, and high-
dose ICS users tended to use a higher number of
additional concomitant medications.
Forty-five per cent of ICS users reported being
affected by 10 or more side effects of a moderate
amount or greater (b2-agonist without ICS patients
29%). There were statistically significant differ-
ences between the four dosage groups for scoringof 31 out of 57 side effect items (Table 3) for which
the majority showed a rising prevalence as dose
increased (Fig. 1). The total ICQ score also showed
a statistically significant rising intensity of per-
ceived side effect with each increasing dose
(Fig. 2). In ICS users prevalence of the most
bothersome perceived side effects (those scored
at a moderate amount or greater) also showed a
rising prevalence as ICS dose increased, for 34
items (Table 4). (ICQ intensity scores for all 57
items, and prevalence for all 57 items scoredX3 by
dose group can be seen in Tables A3 and A4 in the
Appendix A).
Although the fit of the regression model was poorer
than we had hoped (Adj. R2 ¼ 0.108) the significance
of independent variables was nonetheless of interest.
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Figure 2 Intensity of side effect perception by daily
dosage group as measured by the total cumulative side
effect score (0–100) of the ICQ.
J.M. Foster et al.1324When included in the model, mid- and high-dose
ICS group statistically significantly predicted side
effect perception, after controlling for other
factors and covariates (Table 5). Mouth rinsing
was also independently associated with ICQ scor-
ing: perception of side effect was lower for those
who did not rinse their mouth. Low-dose ICS group,
age, gender, smoking status, daily puffs of short
acting b2-agonist and number of other current
medications used did not significantly contribute to
the model.Discussion
Our cross-sectional study is the first to explore the
range and extent of patients’ experiences of ICS
associated side effects. Our results show that
perception scores for 31 side effects including
dysphonia, oral thrush, affected vision, difficulty
sleeping, and symptoms of skin atrophy, were
significantly different between the four daily
dosage groups (b2-agonist without ICS, low-, mid-
and high-dose ICS) (Po0:01), and 24 showed a
rising overall prevalence of side effect perception
with increasing dose.
We identified new side effect perceptions in this
study. Perception of dental decline is as yet
unreported in the pulmonary ICS side effect
literature, but was statistically different between
the four dosage groups in our study. Prevalence in
ICS users ranged from 21% (low-dose group) to 34%(high-dose group), and was only 12% in the
b2-agonist without ICS group. Dental researchers
have reported evidence of greater prevalence of
dental erosion in asthmatic children than in their
matched controls,24 although not all investigators
have been able to show this.25 A detrimental effect
of b2-agonist and ICS use on saliva and plaque pH
causing dental erosion, has been suggested as a
potential mechanism for dental decline.26 Our
results suggest that ICS may have had some
additional influence, since perception of dental
decline indicated a dose response.
Further, patients reported their ‘vision affected’
significantly differently between groups. Preva-
lence ranged from 17% in the b2-agonist without
ICS group to 30% in the low-dose ICS group and 47%
in the high-dose ICS group. Perception of affected
vision may be of considerable interest, due to the
greater risk of subcapsular cataract and open-angle
glaucoma in ICS users reported previously.9–11 This
finding is likely to be independent of any influence
of ocular steroid use, since patients included in our
study were not currently using ocular steroids,
although previous use could not be ruled out.
Further work is needed to clarify the definition of
this perceived side effect.
Other new reported perceptions such as ‘thick
mucus sticking at the back of the throat’, might
contribute to ICS associated dysphonia. Indeed,
hoarseness (49–58% in ICS groups), and inability to
sing (33–42% in ICS groups), were frequently
reported. These perceived side effects have po-
tential social and personal impact on patients who
rely on their voice for their daily work.
We investigated the influence of patient char-
acteristics on side effects reporting. Post inhalation
mouth rinsing was associated with ICQ scoring, in
that ‘not rinsing’ was associated with lower side
effect reporting. A previous study found a smaller
systemic side effect among ICS patients who did
mouth rinse27 but we were unable to show this in
our analysis. Current use of high- and mid-dose ICS
was however independently associated with ICQ
scoring after controlling for other factors and
covariates (including mouth rinsing).
Higher ICS doses are therefore associated with
greater side effect perception. Patients in the high-
dose ICS group for example perceived ‘thin or less
flexible skin’ more than twice as frequently as
those taking low-dose ICS (22% versus 49%) and the
prevalence was only 14% in the patients using
b2-agonist without ICS. Further, scores above 3 on
the scale are likely to represent the most bother-
some side effects. A dose response was apparent
for prevalence of 34 side effect items when scored
atX3 on the ICQ scale. Only 4–33% of low-dose ICS
ARTICLE IN PRESS
Table 4 Prevalence of 34 ‘most bothersome’ (ICQ scoreX3) side effects which showed a dose response trend in
ICS users.
Perceived side effect
item
b2-agonist no ICS
(n ¼ 66)
p400 mg ICS
(n ¼ 109)
401–800 mg ICS
(n ¼ 151)
4800 mg ICS
(n ¼ 69)
n % n % n % n %
Noticeable change to
voice
4 6 18 17 30 20 15 22
Voice gone to back of
throat
6 9 13 12 31 21 15 23
Unable to sing 9 14 16 15 36 24 17 25
Coughing 17 26 33 30 58 39 29 43
Coughing up phlegm 18 27 36 33 65 44 34 51
Thick mucus sticks at
back of throat
13 20 22 20 49 33 27 39
Mucus in your throat 18 28 31 29 58 39 28 41
Clump in throat 10 15 16 15 33 22 23 34
Feeling layer of mucus
stays on back of throat
12 18 21 19 44 29 25 36
Unpleasant feeling in
throat
8 12 20 19 29 20 15 22
Oral thrush 2 3 7 7 14 10 13 19
Bad taste in mouth 6 9 18 17 31 21 17 25
Bad breath 6 9 15 14 31 21 15 22
Loss of taste 4 6 7 6 17 11 9 13
Feeling thirsty 10 15 21 19 43 29 24 35
Wanting to brush teeth 7 11 21 19 31 21 15 22
Bruising easily 4 6 25 23 38 26 31 45
Mood swings 9 14 16 15 27 18 16 23
Easily irritated 10 15 19 17 29 20 17 25
Vision affected 4 6 12 11 30 21 18 27
Sweating 8 12 25 23 45 30 25 37
Night sweating 12 18 27 25 45 31 25 36
Dental decline 5 8 9 8 13 9 9 14
Tiredness 10 15 32 30 60 41 33 49
Recovering from flu
voice
7 11 10 9 27 18 16 24
Painful throat when
talking
6 9 8 7 21 14 13 19
Coughing up thick
mucus
14 22 21 19 52 35 29 44
Thick mucus coming up 13 20 19 18 53 35 28 41
Rough throat 9 14 12 11 26 18 16 23
Itchy feeling back of
throat
17 26 20 19 49 33 26 38
Loss of appetite 5 8 4 4 8 5 6 9
Wanting to drink 13 21 17 16 42 28 23 33
Wanting to rinse mouth 9 14 14 13 29 20 17 25
Difficulty sleeping 13 20 20 19 35 24 23 34
Variation in percentages due to missing data.
Ten items did not show lowest prevalence in non-ICS group (b2-agonist no ICS).
Patient perceived ICS side effects 1325users reported these 34 side effects at such a level
on the scale, compared to 9–51% of high-dose ICS
users.Due to the retrospective design of this study we
acknowledge the potential contributing influence
of underlying disease to our results. Regardless of
ARTICLE IN PRESS
Table 5 Patient variables associated with ICQ side effect scoring.
Variable Coefficient Std error P-value 95% confidence interval
Constant 2.48 0.263 0.000y 1.97, 3.00
Low dose ICS groupz 0.06 0.176 0.732 0.284, 0.404
Mid dose ICS groupz 0.52 0.174 0.003y 0.18, 0.86
High dose ICS groupz 0.62 0.203 0.002y 0.22, 1.02
Mouth rinsingz 0.36 0.130 0.006y 0.61, 0.10
Smokingz 0.15 0.124 0.215 0.40, 0.09
Genderz 0.17 0.112 0.119 0.05, 0.39
Age 0.01 0.004 0.082 0.01, 0.001
Puffs short acting b2-agonist 0.03 0.027 0.230 0.02, 0.09
No. other current medications 0.05 0.028 0.090 0.01, 0.10
The model controlled for other factors and covariates (ICS daily dosage group, age, gender, post-inhalation mouth rinsing,
smoking, daily puffs of short acting b2-agonist and number of other current medications used.
Dependent variable was ICQ score (based on ln(1+average category score).
ySignificant variables (Pp0.01).
zCoefficients for categorical variables are relative to their first group.
J.M. Foster et al.1326any influence of disease, however, it is important to
remember that the subjective associations made by
patients between side effects and medication are
likely to have an equally powerful impact on
medication compliance, whether or not the
strength of such associations can be confirmed
objectively.20
Limitations of our research include potential
selection bias. Although our response rate (56%) is
not atypical for a questionnaire study, we acknowl-
edge that responders may have had a greater
propensity for perceiving ICS side effects as
compared to non-responders, and it is possible that
side effect reporting may have been inflated in all
dose groups as a result. Alternatively, ICS users in
our study may have experienced relatively mild ICS
side effects, since they continue to use ICS
regardless of their perception of side effects.
Further it is important that the ICQ questionnaire
undergoes additional psychometric testing before it
can be widely used. Finally, the design of this
research allowed us to control for systemic steroid
use in the 3 months prior to the survey, but we
could not control for use beyond this point. The
overall attribution of side effects to the use of ICS
may therefore be augmented, and the contra-
distinctions between b2-agonist and ICS side effect
perception might consequently be underestimated.
In conclusion, the measurement of side effects of
ICS by means of a self-report questionnaire is a
useful new method for investigating perceived
adverse effects. The benefit of ICS on importantclinical outcome measures in adults is thought to
plateau at around 400–800 mg daily (BDP equiva-
lent).28 There is growing call for dose titration in
clinical practice to achieve optimal therapy defined
by greatest clinical benefit, with the lowest dose of
inhaled corticosteroids causing minimal side ef-
fects.29,30 Our data complement this since mid to
high daily ICS doses independently predicted side
effect perception scores. Patients taking higher
doses also self-reported a higher intensity and
prevalence of a large number of ICS side effect
items. Our findings are essential to a better
understanding of ICS corollaries, since patients
taking ICS report a range of side effects, which
may not be captured by pharmacovigilance sys-
tems,13 which patients are unlikely to discuss with
clinicians16 and which are likely to contribute to
non-compliance with prescribed regimes.17Acknowledgements
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See Tables A1–A4Table A1 Perceived side effect items considered to be unrelated to ICS use by expert panel and therefore not
included in the ICQ scale.
Items cancelled by expert panel
1. Muscle cramps 7. Tremors
2. Loss of strength 8. More birth marks
3. Bone fractures 9. Weight gain
4. Shaking 10. Veins become difficult to inoculate
5. Heart-beating 11. Skin ulcers
6. Dizziness
Table A2 Patient characteristics for cross-sectional survey by location of data collection.
Aberdeen (n ¼ 106) Groningen (n ¼ 289) P-value
Mean age in years (range) 47.5 (16–84) 52.5 (16–85) o0.01y
% Males 42 49 NS
% Current smokers 23 30 NS
% Rinsed mouth after ICS inhalation 35 79 o0.001
Daily dose group
b2-agonist without ICS (n ¼ 66) 20.8 15.2
p400 mg ICS (n ¼ 109) 42.5 22.1
401–800 mg ICS (n ¼ 151) 17.9 45.7
4800 mg ICS (n ¼ 69) 18.9 17 o0.001
% Using number of puffs of SABA
None 19.8 69.7
1–2 25.7 12.2
3–4 26.7 16.6
More than 5 27.7 1.5 o0.001
% Using number of other current medications
0 medications 46.2 31.1
1–2 medications 39.6 37
More than 2 medications 14.2 31.8 o0.001
As expected countries showed differences which allowed a more representative total sample to be studied. Countries differed in
daily dose of ICS, age, use of post-inhalation mouth rinsing, and use of other concomitant medications, which all tended to be
higher in the Groningen sample. Daily puffs of short-acting ß2-agonist was higher in the Aberdeen sample.
Analyses w2 unless otherwise specified.
yMann–Whitney.
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Table A3 Self-reported intensity scores (0–6) by daily dose group for the 57 patient perceived side effects on
the ICQ.
Perceived side effect
item
b2-agonist no ICS
(n ¼ 66)
p400 mg ICS
(n ¼ 109)
401–800 mg ICS
(n ¼ 151)
4800 mg ICS
(n ¼ 69)
Median IQR Median IQR Median IQR Median IQR
Hoarseness 0.0 0.0–1.0 0.0 0.0–2.0 1.0 0.0–3.0 1.0 0.0–2.5
Rough voice 0.0 0.0–1.0 0.0 0.0–1.0 1.0 0.0–2.0 1.0 0.0–2.0
Noticeable change to
voice
0.0 0.0–0.5 0.0 0.0–1.0 1.0 0.0–2.0 1.0 0.0–2.0
Recovering from flu
voice
0.0 0.0–0.3 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Voice gone to back of
throat
0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Unable to sing 0.0 0.0–0.3 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.5
Loss of speech volume 0.0 0.0–1.0 0.0 0.0–1.0 1.0 0.0–3.0 0.0 0.0–2.0
Feeling of exhaustion
when talking
0.0 0.0–0.3 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Painful throat when
talking
0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0
Feeling people can’t
understand your speech
0.0 0.0–1.0 0.0 0.0–0.0 0.0 0.0–2.0 0.0 0.0–1.0
Breaking voice 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–1.5
Coughing 1.0 0.0–3.0 1.0 0.0–3.0 2.0 0.0–3.0 2.0 1.0–4.0
Coughing up phlegm 1.0 0.0–3.0 1.5 0.0–3.0 2.0 1.0–3.5 3.0 1.0–4.0
Coughing up thick
mucus
0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–3.0 2.0 0.0–3.0
Thick mucus coming up 0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–3.0 2.0 0.0–3.0
Thick mucus sticks at
back of throat
0.0 0.0–2.0 0.0 0.0–2.0 2.0 0.0–3.0 1.0 0.0–3.0
Need to clear throat 1.0 0.0–3.0 1.0 0.0–3.0 3.0 1.0–3.0 2.0 1.0–4.0
Mucus in your throat 1.0 0.0–3.0 1.0 0.0–3.0 2.0 0.0–3.0 2.0 0.0–3.0
Clump in throat 0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–2.0 1.0 0.0–3.0
Feeling layer of mucus
stays on back of throat
0.0 0.0–2.0 1.0 0.0–2.0 1.0 0.0–3.0 1.0 0.0–3.0
Rough throat 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Sore throat 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Unpleasant feeling in
throat
0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–2.0
Dry throat 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–1.0 0.0 0.0–1.0
Itchy feeling on roof of
mouth
0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–0.8
Itchy feeling back of
throat
1.0 0.0–3.0 0.0 0.0–2.0 1.0 0.0–3.0 1.0 0.0–3.0
Oral thrush 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.0
Terrible mouth taste 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0
Taste on teeth 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–1.0
Bad taste in mouth 0.0 0.0–2.0 0.0 0.0–1.0 0.0 0.0–2.0 1.0 0.0–2.5
Bad breath 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0
Change in taste ability 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.5
Loss of taste 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–2.0
Feeling thirsty 0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–3.0 1.0 0.0–3.0
Loss of appetite 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.0
Wanting to drink 1.0 0.0–2.0 0.0 0.0–1.0 1.0 0.0–3.0 1.0 0.0–3.0
Wanting to rinse mouth 0.0 0.0–1.0 0.0 0.0–1.0 1.0 0.0–2.0 1.0 0.0–2.8
Wanting to brush teeth 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0
Wanting to chew gum 0.0 0.0–0.3 0.0 0.0–1.5 0.0 0.0–1.0 0.0 0.0–1.0
Swollen face 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–0.0
Dry skin 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0
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Table A3 (continued )
Perceived side effect
item
b2-agonist no ICS
(n ¼ 66)
p400 mg ICS
(n ¼ 109)
401–800 mg ICS
(n ¼ 151)
4800 mg ICS
(n ¼ 69)
Median IQR Median IQR Median IQR Median IQR
Face dry skin 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–1.0 0.0 0.0–1.0
Bruising easily 0.0 0.0–0.0 0.0 0.0–2.0 0.0 0.0–3.0 1.0 0.0–4.0
Painful bruising for long
period
0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–2.8
Thinner or less flexible
skin
0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–3.0
Grumpy 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–1.0 0.0 0.0–1.0
Mood swings 0.0 0.0–1.8 0.0 0.0–1.5 0.0 0.0–1.0 0.0 0.0–2.0
Easily irritated 0.0 0.0–1.3 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.5
Brittle breaking nails 0.0 0.0–0.0 0.0 0.0–1.5 0.0 0.0–1.0 0.0 0.0–3.0
Hair loss 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–1.0
Vision affected 0.0 0.0–0.0 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–3.0
Sweating 0.0 0.0–1.3 0.0 0.0–2.0 0.0 0.0–3.0 0.5 0.0–3.0
Night sweating 0.0 0.0–2.0 0.0 0.0–2.5 1.0 0.0–3.0 1.0 0.0–3.0
Dental decline 0.0 0.0–0.0 0.0 0.0–0.0 0.0 0.0–0.3 0.0 0.0–1.5
Difficulty sleeping 0.0 0.0–2.0 0.0 0.0–2.0 0.0 0.0–2.0 1.0 0.0–3.0
Tiredness 0.0 0.0–2.0 0.0 0.0–3.0 2.0 0.0–3.0 2.0 0.0–4.0
Dry eyes 0.0 0.0–1.0 0.0 0.0–2.0 0.0 0.0–2.0 0.5 0.0–2.0
Differences in ICQ scores (0–6) between dosage groups (b2-agonist without ICS; p400mg ICS; 401–800mg ICS; 4800 mg ICS)
significant at p0.01.
Table A4 Self-reported prevalence by daily dose group for the 57 patient perceived side effects on the ICQ
scored at ‘a moderate amount’ or greater (ICQ score X3).
Perceived side effect
item
b2-agonist no ICS
(n ¼ 66)
p400 mg ICS
(n ¼ 109)
401–800 mg ICS
(n ¼ 151)
4800 mg ICS
(n ¼ 69)
n % n % n % n %
Hoarseness 6 9 18 17 44 30 17 25
Rough Voice 6 9 15 14 36 24 13 19
Noticeable change to
voice
4 6 18 17 30 20 15 22
Recovering from flu
voice
7 11 10 9 27 18 16 24
Voice gone to back of
throat
6 9 13 12 31 21 15 23
Unable to sing 9 14 16 15 36 24 17 25
Loss of speech volume 7 11 10 9 40 27 16 24
Feeling of exhaustion
when talking
8 12 12 11 33 22 14 20
Painful throat when
talking
6 9 8 7 21 14 13 19
Feeling people can’t
understand your speech
6 9 7 7 30 20 13 19
Breaking voice 10 15 12 11 28 19 11 16
Coughing 17 26 33 30 58 39 29 43
Coughing up phlegm 18 27 36 33 65 44 34 51
Coughing up thick mucus 14 22 21 19 52 35 29 44
Thick mucus coming up 13 20 19 18 53 35 28 41
Thick mucus sticks at
back of throat
13 20 22 20 49 33 27 39
Patient perceived ICS side effects 1329
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Table A4 (continued )
Perceived side effect
item
b2-agonist no ICS
(n ¼ 66)
p400 mg ICS
(n ¼ 109)
401–800 mg ICS
(n ¼ 151)
4800 mg ICS
(n ¼ 69)
n % n % n % n %
Need to clear throat 18 28 39 36 74 50 29 43
Mucus in your throat 18 28 31 29 58 39 28 41
Clump in throat 10 15 16 15 33 22 23 34
Feeling layer of mucus
stays on back of throat
12 18 21 19 44 29 25 36
Rough throat 9 14 12 11 26 18 16 23
Sore throat 6 9 14 13 26 18 11 16
Unpleasant feeling in
throat
8 12 20 19 29 20 15 22
Dry throat 4 6 22 20 18 12 8 12
Itchy feeling on roof of
mouth
8 12 16 15 18 12 8 12
Itchy feeling back of
throat
17 26 20 19 49 33 26 38
Oral thrush 2 3 7 7 14 10 13 19
Terrible mouth taste 9 14 13 12 34 23 16 23
Taste on teeth 3 5 11 10 13 9 7 10
Bad taste in mouth 6 9 18 17 31 21 17 25
Bad breath 6 9 15 14 31 21 15 22
Change in taste ability 4 6 9 8 21 14 9 13
Loss of taste 4 6 7 6 17 11 9 13
Feeling thirsty 10 15 21 19 43 29 24 35
Loss of appetite 5 8 4 4 8 5 6 9
Wanting to drink 13 21 17 16 42 28 23 33
Wanting to rinse mouth 9 14 14 13 29 20 17 25
Wanting to brush teeth 7 11 21 19 31 21 15 22
Wanting to chew gum 6 9 19 17 27 18 9 13
Swollen face 0 0 6 6 9 6 4 6
Dry skin 11 17 20 18 25 17 14 22
Face dry skin 8 12 15 14 24 16 10 15
Bruising easily 4 6 25 23 38 26 31 45
Painful bruising for long
period
2 3 17 16 20 14 17 25
Thinner or less flexible
skin
4 6 16 15 21 14 21 31
Grumpy 9 14 14 13 17 11 13 19
Mood swings 9 14 16 15 27 18 16 23
Easily irritated 10 15 19 17 29 20 17 25
Brittle breaking nails 5 8 19 17 21 14 18 26
Hair loss 2 3 7 6 21 14 9 13
Vision affected 4 6 12 11 30 21 18 27
Sweating 8 12 25 23 45 30 25 37
Night sweating 12 18 27 25 45 31 25 36
Dental decline 5 8 9 8 13 9 9 14
Difficulty sleeping 13 20 20 19 35 24 23 34
Tiredness 10 15 32 30 60 41 33 49
Dry eyes 9 14 20 19 28 19 16 24
Variation in percentages due to missing data.
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